January 14, 2026, was a big day for tech funding. Investors put a lot of money into AI, robotics, and cybersecurity. Skild AI got $1. 4 billion to build a "brain" for robots. This brain can control different types of robots, like humanoids and drones. The company wants to make robots smarter and mor
Medpace, a notable player in the biotech industry, has been making waves with its recent performance. The company's stock has been under the microscope, showing signs of a potential early buy point. This comes at a time when biotech funding is seeing a much-needed improvement, which could be a game-
A prominent figure in the biotech world has raised a red flag. Noubar Afeyan, a well-known investor, has expressed concerns about a growing resistance to science in the United States. He believes this trend could have serious consequences. In a recent letter to investors, Afeyan warned that rejecti
The biotech and life sciences industry is at a crossroads. After a few tough years, there's a glimmer of hope for recovery. The need for new medical treatments is huge. There are many diseases that still don't have effective treatments. The pharmaceutical industry is also under pressure. Many of the
On January 8, 2026, investors poured money into startups working on AI, healthcare, and other cutting-edge tech. The big winners included xAI, which raised a whopping $20 billion to build advanced AI systems, and Cyera, which got $400 million to help companies keep their AI secure. In the world of
Lilly, a big name in medicine, is making a big move. They're buying Ventyx, a smaller company with a promising lineup of drugs. Ventyx's focus? Inflammation. They're working on small molecules that could treat a wide range of diseases caused by chronic inflammation. Think heart disease, brain disord
Big Pharma companies are in a rush to buy biotech firms. Why? They face a huge problem. Many of their top-selling drugs will soon lose patent protection. This is called the "patent cliff. " By 2032, they could lose over $170 billion in sales. To avoid this, they need new drugs fast. That's where bi
Cathie Wood, a well-known investor, made a significant move on the last trading day of 2025. She invested $1. 33 million in Intellia Therapeutics, a company focused on gene editing. This investment is notable because Intellia's stock has not performed well this year, dropping by 22%. Despite this, W
The stock market is ending the year on a down note. The Dow Jones Industrial Average is lower today. Investors are reacting to some big news from the FDA. This news has caused biotech stocks to drop. It's a reminder that the market can be unpredictable. The FDA's announcement has sent shockwaves th
A fresh startup in Albuquerque has just landed a cool $2. 5 million to shake up the world of DNA and RNA sequencing. This isn't just any tech—it's the kind that could change how we tackle diseases, from custom cancer treatments to predicting health risks. The brains behind Daisy Genomics, Emily Mil
